At a glance
- Originator Merck & Co
- Class Antiglaucomas
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 12 Dec 1994 No-Development-Reported for Glaucoma in USA (Ophthalmic)